Iodine-131-SGMIB anti-HER2 monoclonal antibody

Drug Profile

Iodine-131-SGMIB anti-HER2 monoclonal antibody

Alternative Names: 131I-SGMIB anti-HER2-VHH1; [131I]-SGMIB Anti-HER2 VHH1; CAM-H2; Iodine-131-SGMIB anti-HER2 VHH1

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Camel-IDS
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Immunomodulators; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 01 Jun 2018 Pharmacokinetics data from a phase I trial in Breast cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 17 Jan 2018 Camel-IDS completes a phase I trial in Breast cancer (Diagnosis) in Belgium (IV) (NCT02683083)
  • 01 Feb 2016 Phase-I clinical trials in Breast cancer (Diagnosis) in Belgium (IV) (NCT02683083)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top